David Shaw’s Puma Biotechnology PBYI Stock Holding History

David Shaw’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-41,000	Closed	-$834K	–	3841
2018 Q4	$834K	Hold	41,000	–	–	﹤0.01%	2787
2018 Q3	$1.88M	Hold	41,000	–	–	﹤0.01%	2242
2018 Q2	$2.42M	Hold	41,000	–	–	﹤0.01%	2081
2018 Q1	$2.79M	Hold	41,000	–	–	﹤0.01%	1812
2017 Q4	$4.05M	Buy	41,000 +10,600	+35%	+$1.19M	0.01%	1631
2017 Q3	$3.64M	Buy	30,400 +20,400	+204%	+$1.9M	0.01%	1609
2017 Q2	$874K	Hold	10,000	–	–	﹤0.01%	2495
2017 Q1	$372K	Buy	+10,000	New	+$365K	﹤0.01%	2876
2016 Q2	–	Sell	-30,100	Closed	-$884K	–	3480
2016 Q1	$884K	Hold	30,100	–	–	﹤0.01%	2429
2015 Q4	$2.36M	Buy	+30,100	New	+$2.36M	﹤0.01%	2008
2015 Q1	–	Sell	-22,100	Closed	-$4.18M	–	3900
2014 Q4	$4.18M	Buy	22,100 +10,000	+83%	+$2.22M	0.01%	1703
2014 Q3	$2.89M	Buy	+12,100	New	+$2.48M	﹤0.01%	1947

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's PBYI Position: Q2 2026 in Review

David Shaw reduced its Puma Biotechnology (PBYI) stake by 9.9% in Q2 2026, selling an estimated $255K and leaving 316,343 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

David Shaw first reported a position in PBYI in Q2 2013 and has held it in 47 quarters since. The position peaked at $93.6M in Q1 2018. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

David Shaw held 316,343 shares of Puma Biotechnology worth $2.57M as of Q2 2026.
David Shaw sold 34,892 Puma Biotechnology shares in Q2 2026, an estimated $255K.
Puma Biotechnology made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2985 holding.
David Shaw first reported a position in Puma Biotechnology in Q2 2013 and has held it in 47 quarters since.
David Shaw's Puma Biotechnology position peaked at $93.6M in Q1 2018.
160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.